Business Wire

TOSHIBA-MATERIALS

20.7.2022 06:07:10 CEST | Business Wire | Press release

Share
Toshiba Materials in Major Investment to Increase Silicon Nitride Ball Production Capacity

Toshiba Materials Co., Ltd. (President: Katsuaki Aoki) today announced a major investment in a new manufacturing facility for silicon nitride balls on the same site as its headquarters in Yokohama, Japan. The project has a budget of over 5-billion yen (approx. US$38 million) and is expected to see production start in November 2023. It will increase capacity by 50% against fiscal year 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006169/en/

Continued advances in automobile electrification requires solutions that go beyond higher voltage batteries and shorter charging times. One measure to reduce costs and improve performance is the integration of motors and inverters. Although this increases risk of electrolytic corrosion[1] in motor bearings[2] , the problem can be overcome with hybrid bearings, which replace standard steel balls with ceramic balls with steel inner and outer races. Advantages of high reliability, excellent strength and superior wear resistance are increasingly positioning ceramic balls as the solution of choice.

Toshiba Group has long recognized the potential of fine ceramic products, and won basic patents for silicon nitride compounds as early as 1974. Today, Toshiba Materials, spun off from Toshiba in October 2003, continues to advance R&D and manufacturing of silicon nitride balls, recognized for their reliability and for delivering the highest mechanical performance of any silicon balls. Its experience and record of success in bearing balls that meet demands for high speed rotation and anti-electrolytic corrosion, including machine tools, wind power generators and rolling stock, have won the company about 50% of the world market[3] . With significant increases in demand for bearings for electric vehicles on the horizon, Toshiba Materials has now decided to make this significant investment in increasing capacity.

The new production facility will be built on the company’s headquarters site, where an old building, no longer in use, will be demolished to make way for it. The new facility should be seen as the first phase of expansion, and Toshiba Materials is already considering further expansions to meet future demand growth.

Toshiba Materials will continue stable supply of high quality products, and will contribute to increased use of environmentally friendly electric vehicles.

Features of silicon nitride balls

  • Low density: less than half the weight of a steel ball of the same size
  • High heat resistance
  • Resistant to electrolytic corrosion, as it is an insulator
  • Resistant to corrosion and rust caused by acids and alkalis
  • A non-magnetic material, not easily affected by a strong magnetic field

1 Electrolytic corrosion: damage to a bearing caused by a current flowing through it.
2 Bearing: A part that allows a shaft to rotate smoothly in a machine. Formed with an inner race, balls, and outer race.
3 Toshiba Materials’ investigation, July 2022

About Toshiba Materials

Toshiba Materials Co., Ltd. (http://www.toshiba-tmat.co.jp/en/ ) was spun off from Toshiba Corporation in 2003. With material designing technology as its core capacity, Toshiba Materials supplies materials and components essential for society’s development. Main products include metallic materials, components, fine ceramics parts and chemical materials. In the year ended March 31, 2021, net sales totaled 24.3 billion yen (approx. USD 210 million).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye